Massimo Di Maio/X
Jun 1, 2025, 16:37
Massimo Di Maio: Overall Survival Analysis Should NOT be Adjusted for Subsequent Treatments
Massimo Di Maio, Associate Professor of Medical Oncology at Department of Oncology, University of Turin, shared a post on X:
“Subsequent treatments received after progression are integral part of the patients’ clinical management, NOT a confounding factor for the real impact of experimental therapy. In my opinion, overall survival analysis should NOT be adjusted for subsequent treatments.”
More posts featuring Massimo Di Maio on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 11, 2025, 13:30
Aug 11, 2025, 13:09
Aug 11, 2025, 12:48
Aug 11, 2025, 12:32
Aug 11, 2025, 12:27
Aug 11, 2025, 12:21